Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States

BACKGROUND: Immune-related adverse events (irAEs) are a common phenomenon in cancer patients treated with immune checkpoint inhibitors (ICIs). Surprisingly, the toxicity burdens of these irAEs have not been illustrated clearly. In this study, we analyzed irAEs for seven FDA-approved ICIs in cancer t...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Fan, Shay, Chloe, Abousaud, Marin, Tang, Chris, Li, Yamin, Qin, Zhaohui, Saba, Nabil F., Teng, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814433/
https://www.ncbi.nlm.nih.gov/pubmed/36600271
http://dx.doi.org/10.1186/s13046-022-02568-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814433/
https://www.ncbi.nlm.nih.gov/pubmed/36600271
http://dx.doi.org/10.1186/s13046-022-02568-y

Ejemplares similares